PA
CTMX icon

Profund Advisors’s CytomX Therapeutics CTMX Stock Holding History

Profund Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$418K Buy
111,378
+6,843
+7% +$26.1K 0.01% 629
2026
Q1 		$491K Buy
104,535
+5,902
+6% +$30K 0.02% 555
2025
Q4 		$420K Buy
+98,633
New +$375K 0.01% 643

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Profund Advisors's CTMX Position: Q2 2026 in Review

Profund Advisors increased its CytomX Therapeutics (CTMX) stake by 6.5% in Q2 2026, buying an estimated $26.1K and bringing the position to 111,378 shares worth $418K. The position accounts for 0.01% of the portfolio, ranked #629.

Profund Advisors first reported a position in CTMX in Q4 2025 and has held it in 3 quarters since. The position peaked at $491K in Q1 2026. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Profund Advisors held 111,378 shares of CytomX Therapeutics worth $418K as of Q2 2026.
  • Profund Advisors bought 6,843 CytomX Therapeutics shares in Q2 2026, an estimated $26.1K.
  • CytomX Therapeutics made up 0.01% of Profund Advisors's portfolio in Q2 2026, its #629 holding.
  • Profund Advisors first reported a position in CytomX Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Profund Advisors's CytomX Therapeutics position peaked at $491K in Q1 2026.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.